Inactive Instrument

Highlights Curative Biotechnology, Inc. Other OTC

Equities

CTYX

US20786Q2093

Highlights

Unlock all the news: Be the first to know and act before the market!

Curative Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/05	CI
Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.	25/11	CI
Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.	07/23/07	CI
Curative Biotechnology, Inc. Announces Establishment of Japanese Subsidiary for Licensing Transactions and Asset Acquisitions	07/23/07	CI
Curative Biotechnology, Inc. Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study	05/23/05	CI
Curative Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	17/22/17	CI
Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million.	07/22/07	CI
Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million.	31/22/31	CI
Curative Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	01/22/01	CI
Curative Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	30/22/30	CI
Curative Biotechnology, Inc. has filed an IPO.	15/22/15	CI
Curative Biotechnology Announces Cooperative Research and Development Agreement with the National Eye Institute	21/22/21	CI
Curative Biotechnology Announces Ocular Tolerance Evaluation of Metformin Eye Drop Formulations for Treatment of Macular Degeneration	24/21/24	CI
Curative Biotechnology Announces IMT504 License For Development Of Proprietary Next-Gen COVID-19 Vaccine	07/21/07	CI
Connectyx Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye Disease	04/21/04	CI
Connectyx Announces Grant of License from National Institutes of Health for Use of Novel Monoclonal Antibody to Treat Glioblastoma	16/20/16	CI
Connectyx Technologies Holdings Group, Inc. Announces Strategic Relationship with Mid-Atlantic Biotherapeutics, Inc. for Treatment of Symptomatic Rabies	27/20/27	CI
Connectyx in Licensing Discussions for Novel Monoclonal Antibody to Treat Pediatric Glioblastoma	06/20/06	CI
Connectyx Technologies Holdings Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	19/20/19	CI
Connectyx Launches MedFlash Canada	04/13/04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Curative Biotechnology, Inc. Other OTC

Equities

CTYX

US20786Q2093

Highlights

Filters